Compare Stocks: ALT, KOD, NUVB, and BHVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.23 -1.5%	$3.01	$2.56 ▼ $6.44	$638.02M	0.18	4.35 million shs	2.55 million shs
BHVN Biohaven	$15.90 +1.3%	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.03 million shs	2.26 million shs
KOD Kodiak Sciences	$36.36 -3.0%	$40.34	$8.30 ▼ $47.84	$2.36B	2.18	578,664 shs	460,151 shs
NUVB Nuvation Bio	$6.73 -2.9%	$6.32	$2.99 ▼ $9.75	$2.43B	1.52	5.50 million shs	5.27 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-1.52%	-0.31%	+5.21%	+19.19%	-12.23%
BHVN Biohaven	+0.76%	-1.14%	+15.78%	+46.64%	-1.91%
KOD Kodiak Sciences	-3.04%	-7.06%	-15.22%	+17.10%	+324.27%
NUVB Nuvation Bio	-2.82%	-3.79%	+4.26%	+39.77%	+113.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.23 -1.5%	$3.01	$2.56 ▼ $6.44	$638.02M	0.18	4.35 million shs	2.55 million shs
BHVN Biohaven	$15.90 +1.3%	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.03 million shs	2.26 million shs
KOD Kodiak Sciences	$36.36 -3.0%	$40.34	$8.30 ▼ $47.84	$2.36B	2.18	578,664 shs	460,151 shs
NUVB Nuvation Bio	$6.73 -2.9%	$6.32	$2.99 ▼ $9.75	$2.43B	1.52	5.50 million shs	5.27 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-1.52%	-0.31%	+5.21%	+19.19%	-12.23%
BHVN Biohaven	+0.76%	-1.14%	+15.78%	+46.64%	-1.91%
KOD Kodiak Sciences	-3.04%	-7.06%	-15.22%	+17.10%	+324.27%
NUVB Nuvation Bio	-2.82%	-3.79%	+4.26%	+39.77%	+113.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$14.33	343.76% Upside
BHVN Biohaven	2.65	Moderate Buy	$18.94	19.10% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	32.41% Upside
NUVB Nuvation Bio	2.69	Moderate Buy	$13.00	93.16% Upside

Current Analyst Ratings Breakdown

Latest ALT, KOD, NUVB, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/18/2026	NUVB Nuvation Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00
8/11/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
8/7/2026	NUVB Nuvation Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$40K	15,707.49	N/A	N/A	$2.44 per share	1.32
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.08 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
NUVB Nuvation Bio	$62.90M	37.57	N/A	N/A	$0.72 per share	9.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.78	N/A	N/A	N/A	-214,860.98%	-31.41%	-26.96%	11/5/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)

Latest ALT, KOD, NUVB, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/11/2026	Q2 2026	ALT Altimmune	-$0.1355	-$0.12	+$0.0155	-$0.12	$0.00 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.07	26.78	26.78
BHVN Biohaven	21.23	4.73	4.73
KOD Kodiak Sciences	N/A	2.49	2.49
NUVB Nuvation Bio	0.96	8.37	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
BHVN Biohaven	88.78%
KOD Kodiak Sciences	89.06%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
BHVN Biohaven	13.80%
KOD Kodiak Sciences	44.40%
NUVB Nuvation Bio	30.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	194.52 million	191.41 million	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
KOD Kodiak Sciences	90	62.85 million	34.94 million	Optionable
NUVB Nuvation Bio	60	351.12 million	245.40 million	Optionable

ALT, KOD, NUVB, and BHVN Headlines

Recent News About These Companies

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

September 3 at 10:55 AM | zacks.com

Nuvation Bio to Participate in Upcoming Investor Conferences

September 2 at 4:05 PM | prnewswire.com

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

August 31, 2026 | zacks.com

Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts

August 26, 2026 | seekingalpha.com

Gary Hattersley Sells 100,000 Shares of Nuvation Bio (NYSE:NUVB) Stock

August 22, 2026 | insidertrades.com

Bank of America Corp DE Sells 589,599 Shares of Nuvation Bio Inc. $NUVB

August 22, 2026 | marketbeat.com

Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells $709,000.00 in Stock

August 21, 2026 | marketbeat.com

JPMorgan says Nuvation Bio stock could double

August 20, 2026 | msn.com

Nuvation Bio Inc.: Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

August 20, 2026 | finanznachrichten.de

Nuvation Bio Gets FDA Fast Track Designation for Safusidenib in IDH1-Mutant Glioma Treatment

August 20, 2026 | finance.yahoo.com

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

August 20, 2026 | prnewswire.com

Nuvation Bio Inc. (NUVB)

August 20, 2026 | finance.yahoo.com

Nuvation Bio (NYSE:NUVB) Trading Up 6.7% - Still a Buy?

August 18, 2026 | marketbeat.com

Nuvation wins new Overweight at J.P. Morgan on launch trajectory for lead drug

August 18, 2026 | seekingalpha.com

Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know

August 18, 2026 | zacks.com

Nuvation Bio (NYSE:NUVB) Coverage Initiated by Analysts at JPMorgan Chase & Co.

August 18, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Reduces Stake in Nuvation Bio Inc. $NUVB

August 16, 2026 | marketbeat.com

Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Brokers Set Expectations for Nuvation Bio FY2026 Earnings

August 11, 2026 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALT, KOD, NUVB, and BHVN Company Descriptions

Altimmune NASDAQ:ALT

$3.23 -0.05 (-1.52%)

As of 09/3/2026 04:00 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Biohaven NYSE:BHVN

$15.90 +0.21 (+1.34%)

As of 09/3/2026 03:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Kodiak Sciences NASDAQ:KOD

$36.36 -1.14 (-3.04%)

As of 09/3/2026 04:00 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nuvation Bio NYSE:NUVB

$6.73 -0.20 (-2.89%)

As of 09/3/2026 03:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALT, KOD, NUVB, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALT, KOD, NUVB, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALT, KOD, NUVB, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALT, KOD, NUVB, and BHVN Company Descriptions

Altimmune NASDAQ:ALT

Biohaven NYSE:BHVN

Kodiak Sciences NASDAQ:KOD

Nuvation Bio NYSE:NUVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALT, KOD, NUVB, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALT, KOD, NUVB, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALT, KOD, NUVB, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALT, KOD, NUVB, and BHVN Company Descriptions

Altimmune NASDAQ:ALT

Biohaven NYSE:BHVN

Kodiak Sciences NASDAQ:KOD

Nuvation Bio NYSE:NUVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools